Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 10,000 | |||
5 mg | 在庫あり | ¥ 22,500 | |||
10 mg | 在庫あり | ¥ 42,500 | |||
25 mg | 在庫あり | ¥ 85,500 | |||
50 mg | 在庫あり | ¥ 128,000 | |||
100 mg | 在庫あり | ¥ 180,000 |
説明 | LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors. |
ターゲット&IC50 | ALK2:1.3 nM |
In vitro | LDN-212854 (6 mg/kg, i.p.) effectively inactivates ALK2 signaling in vivo and efficiently inhibits ectopic ossification in inducible transgenic ALK2 mice mutants with progressive ankylosis. |
In vivo | In C2C12 myoblasts, LDN-212854 demonstrates a higher selectivity for BMP6 over BMP4 in inducing osteogenic differentiation, compared to the osteogenic differentiation induced by BMP6 and BMP4. |
別名 | LDN212854, BMP Inhibitor III |
分子量 | 406.48 |
分子式 | C25H22N6 |
CAS No. | 1432597-26-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
2eq.HCl: 20.3 mg/mL (50 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LDN-212854 1432597-26-6 Angiogenesis Stem Cells Tyrosine Kinase/Adaptors ALK TGF-beta/Smad LDN212854 HCC Huh7 EpCAM Inhibitor BMP BMP Inhibitor III Transforming growth factor beta receptors BMP9-ID1 signaling MT cell heterotopic ossification FOP model TGF-β Receptor LDN 212854 inhibit BMPR2 cell inhibitor